1. Home
  2. PGY vs URGN Comparison

PGY vs URGN Comparison

Compare PGY & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$15.28

Market Cap

971.3M

Sector

Finance

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$29.24

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
URGN
Founded
2016
2004
Country
United States
United States
Employees
518
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.3M
1.1B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
PGY
URGN
Price
$15.28
$29.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
7
Target Price
$34.50
$29.29
AVG Volume (30 Days)
3.4M
873.1K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$14.27
$129.09
Revenue Next Year
$14.39
$70.96
P/E Ratio
$13.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.40
$3.42
52 Week High
$44.99
$30.00

Technical Indicators

Market Signals
Indicator
PGY
URGN
Relative Strength Index (RSI) 63.10 75.83
Support Level $10.78 $17.86
Resistance Level $15.57 $30.00
Average True Range (ATR) 0.87 1.84
MACD 0.12 0.35
Stochastic Oscillator 56.18 84.44

Price Performance

Historical Comparison
PGY
URGN

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: